Autopsy report · NCT07282548

Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies

“Withdrawn prior to enrolment after review of updated safety data”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Ipsen

Sponsor type

Industry

Conditions

Follicular Lymphoma

Participants

0

Trials that died the same way

• A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
  “Study was withdrawn prior to enrolment due to business decision.” (65% match in meaning)
• Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration
  “Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.” (64% match in meaning)
• Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
  “Withdrawn for administrative reasons.” (63% match in meaning)
• Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
  “Withdrawn: study halted prematurely, prior to enrollment of first participant” (61% match in meaning)
• Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
  “Study is withdrawn and no one enrolled due to changes in personnel” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.